Yahoo Web Search

Search results

  1. Loren David Walensky is an American physician-scientist and pediatric oncologist at the Dana–Farber Cancer Institute since 2003 and a professor of pediatrics at the Dana–Farber/Harvard Cancer Center. He researches peptides and oncogenic pathways. In 2013, Walensky became director of the joint MD/PhD program at Harvard Medical School.

    • 3
    • .mw-parser-output .marriage-line-margin2px{line-height:0;margin-bottom:-2px}.mw-parser-output .marriage-line-margin3px{line-height:0;margin-bottom:-3px}.mw-parser-output .marriage-display-ws{display:inline;white-space:nowrap}, Rochelle Walensky ​(m. 1995)​
  2. May 1, 2019 · Loren David Walensky | Department of Biological Chemistry & Molecular Pharmacology. Loren David Walensky, M.D., Ph.D. Professor of Pediatrics. 617-355-6369. Email. Publications View. Design of stapled antimicrobial peptides that are stable, nontoxic and kill antibiotic-resistant bacteria in mice.

  3. People also ask

  4. Professional History. Dr. Loren Walensky received his MD and PhD degrees from Johns Hopkins University School of Medicine in 1997. He trained at the Boston Combined Residency Program in pediatrics, completed a fellowship in pediatric hematology-oncology at Dana-Farber and Boston Children's Hospital, and is board-certified in pediatric ...

  5. Professor of Pediatrics. Summary. Description. Chemical biology of deregulated apoptotic and transcriptional pathways in cancer.

  6. Professor of Pediatrics. The Walensky laboratory focuses on the chemical biology of deregulated apoptotic and transcriptional pathways in cancer. Our goal is to develop an arsenal of new compounds-a “chemical toolbox”-to investigate and block protein interactions that cause cancer.

  7. Biography. Dr. Walensky received his MD and PhD degrees from Johns Hopkins University School of Medicine in 1997. He trained at the Boston Combined Residency Program in pediatrics, completed a fellowship in pediatric hematology-oncology at Dana-Farber and Boston Children's Hospital, and is board-certified in pediatric hematology/oncology. Dr.

  8. 486. 2010. The challenge of drugging undruggable targets in cancer: lessons learned from targeting BCL-2 family members. GL Verdine, LD Walensky. Clinical cancer research 13 (24), 7264-7270. , 2007. 475. 2007. Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma.

  1. People also search for